Clinical trial · Interventional
A New Supplement for the Immune Response to HPV Infection
Ellagic Acid and Annona Muricata May Modulate the Immune Response to High Risk HPV Infection. A Randomized, Controlled Trial.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate whether a supplement in which ellagic acid plus annona muricata are combined, may modulate the immune response to high risk HPV infection. Sixty women will be enrolled in a randomized, controlled study, having a histological diagnosis of L-SIL correlated with high rish HPV types infection. Main outcome measure is the activation of onco suppressor protein by the supplement and secondary outcome is the clearance of HPV infection in the treated group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HPV Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ellagic acid + annona muricata | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- supplement
- interventionNames
- Drug: ellagic acid + annona muricata
- type
- PLACEBO_COMPARATOR
- label
- not intervention
- interventionNames
- Drug: ellagic acid + annona muricata
Primary outcomes (1)
- measure
- variation of onco suppressor protein expression from basal values. The expression variations are represented by the different percentage of positive cells
- timeFrame
- 6 months
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * women with high risk HPV infection * histological diagnosis of L-SIL Exclusion Criteria: * women with no high risk HPV infection * women without histological diagnosis of L-SIL
References
Publications (0)
Data not yet available